Strewngth in Science for 25 Years
video image

For 25 years, Cytokinetics has been developing potential medicines to improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Pick a Year
Reported results from METEORIC-HF, Phase 3 clinical trial of omecamtiv mecarbil in HFrEF 2022 Participated in FDA advisory committee for omecamtiv mecarbil 2022 Started COURAGE-ALS open-label extension study of reldesemtiv in ALS 2022 Began Phase 2 cohort 4 of REDWOOD-HCM clinical trial of aficamten in nHCM 2022 Started Phase 3 SEQUOIA-HCM clinical trial of aficamten in oHCM 2022 FDA accepted New Drug Application for omecamtiv mecarbil for HFrEF 2022 Announced results of REDWOOD-HCM, Phase 2 clinical trial of aficamten in HCM 2021 Started COURAGE-ALS, Phase 3 clinical trial of reldesemtiv 2021 Started FOREST-HCM, an open-label extension study of aficamten 2021 Received orphan drug designation for aficamten for the treatment of HCM 2021 Regained rights to commercialize omecamtiv mecarbil from Amgen and Servier 2020 Reported results of GALACTIC-HF, Phase 3 clinical trial of omecamtiv mecarbil in HFrEF, and simultaneous publication in NEJM 2020 Announced licensing collaboration and royalty monetization deals with Ji Xing Pharmaceuticals for aficamten 2020 Received fast track designation for omecamtiv mecarbil in heart failure 2020 Reldesemtiv received orphan drug designation for ALS 2020 Initiated REDWOOD-HCM, a Phase 2 clinical trial of aficamten 2020 Announced results from FORTITUDE-ALS, Phase 2 clinical trial of reldesemtiv in ALS 2019 Started METEORIC-HF, second Phase 3 clinical trial of omecamtiv mecarbil in HFrEF 2019 Initiated Phase 1 study of CK-3828136 2019 Initiated Phase 1 study of aficamten 2018 Reported results of VITALITY-ALS, Phase 3 clinical trial of tirasemtiv in ALS 2017 Initiated FORTITUDE-ALS, Phase 2 clinical trial of reldesemtiv in ALS 2017 Sold to Royalty Pharma a royalty on omecamtiv mecarbil for $100 million 2017 Initiated GALACTIC-HF, Phase 3 clinical trial of omecamtiv mecarbil in HFrEF 2016 Initiated VIGOR-ALS, open-label extension trial of tirasemtiv 2016 Expanded collaboration with Astellas for reldesemtiv in ALS and granted option right for tirasemtiv 2016 Introduced new corporate brand 2015 Initiated VITALITY-ALS, Phase 3 clinical trial of tirasemtiv 2015 Expanded strategic alliance with Astellas to include neuromuscular indications 2014 Reported results of BENEFIT-ALS, Phase 2B clinical trial of tirasemtiv in ALS 2014 Initiated Phase 1 clinical trial of reldesemtiv 2013 Strategic alliance with Astellas for reldesemtiv 2013 Initiated Phase 2B clinical trial of omecamtiv mecarbil 2011 Initiated Phase 2A clinical trial of tirasemtiv in ALS 2010 Initiated Phase 1 clinical trial of tirasemtiv 2009 Amgen exercised option for omecamtiv mecarbil 2009 Strategic realignment with focus on muscle biology 2008 Selected skeletal muscle troponin activator for development 2008 Initiated Phase 2 of clinical trial of omecamtiv mecarbil in heart failure 2007 Strategic alliance and equity purchase with Amgen 2006 Initiated Phase 1 clinical trial of omecamtiv mecarbil 2005 Selected second cardiac myosin activator for development 2004 Initiated Phase 2 clinical trial of ispinesib 2004 Completed initial public offering 2004 Completed mezzanine (Series E) financing 2003 Selected cardiac muscle activator for development 2003 Initiated Phase 1 clinical trial of ispinesib 2002 Selected KSP inhibitor for development 2001 Series C financing 2000 Series B financing 1999 Series A financing 1998 Company operations begin 1998 Cytokinetics is founded 1998 Reported results from METEORIC-HF, Phase 3 clinical trial of omecamtiv mecarbil in HFrEF 2022 Participated in FDA advisory committee for omecamtiv mecarbil 2022 Started COURAGE-ALS open- label extension study of reldesemtiv in ALS 2022 Began Phase 2 cohort 4 of REDWOOD-HCM clinical trial of aficamten in nHCM 2022 Started Phase 3 SEQUOIA- HCM clinical trial of aficamten in oHCM 2022 FDA accepted New Drug Application for omecamtiv mecarbil for HFrEF 2022 Announced results of REDWOOD-HCM, Phase 2 clinical trial of aficamten in HCM 2021 Started COURAGE-ALS, Phase 3 clinical trial of reldesemtiv 2021 Started FOREST-HCM, an open-label extension study of aficamten 2021 Received orphan drug designation for aficamten for the treatment of HCM 2021 Regained rights to commercialize omecamtiv mecarbil from Amgen and Servier 2020 Reported results of GALACTIC-HF, Phase 3 clinical trial of omecamtiv mecarbil in HFrEF, and simultaneous publication in NEJM 2020 Announced licensing collaboration and royalty monetization deals with Ji Xing Pharmaceuticals for aficamten 2020 Received fast track designation for omecamtiv mecarbil in heart failure 2020 Reldesemtiv received orphan drug designation for ALS 2020 Initiated REDWOOD-HCM, a Phase 2 clinical trial of aficamten 2020 Announced results from FORTITUDE-ALS, Phase 2 clinical trial of reldesemtiv in ALS 2019 Started METEORIC-HF, second Phase 3 clinical trial of omecamtiv mecarbil in HFrEF 2019 Initiated Phase 1 study of CK-3828136 2019 Initiated Phase 1 study of aficamten 2018 Reported results of VITALITY- ALS, Phase 3 clinical trial of tirasemtiv in ALS 2017 Initiated FORTITUDE-ALS, Phase 2 clinical trial of reldesemtiv in ALS 2017 Sold to Royalty Pharma a royalty on omecamtiv mecarbil for $100 million 2017 Initiated GALACTIC-HF, Phase 3 clinical trial of omecamtiv mecarbil in HFrEF 2016 Initiated VIGOR-ALS, open- label extension trial of tirasemtiv 2016 Expanded collaboration with Astellas for reldesemtiv in ALS and granted option right for tirasemtiv 2016 Introduced new corporate brand 2015 Initiated VITALITY-ALS, Phase 3 clinical trial of tirasemtiv 2015 Expanded strategic alliance with Astellas to include neuromuscular indications 2014 Reported results of BENEFIT- ALS, Phase 2B clinical trial of tirasemtiv in ALS 2014 Initiated Phase 1 clinical trial of reldesemtiv 2013 Strategic alliance with Astellas for reldesemtiv 2013 Initiated Phase 2B clinical trial of omecamtiv mecarbil 2011 Initiated Phase 2A clinical trial of tirasemtiv in ALS 2010 Initiated Phase 1 clinical trial of tirasemtiv 2009 Amgen exercised option for omecamtiv mecarbil 2009 Strategic realignment with focus on muscle biology 2008 Selected skeletal muscle troponin activator for development 2008 Initiated Phase 2 of clinical trial of omecamtiv mecarbil in heart failure 2007 Strategic alliance and equity purchase with Amgen 2006 Initiated Phase 1 clinical trial of omecamtiv mecarbil 2005 Selected second cardiac myosin activator for development 2004 Initiated Phase 2 clinical trial of ispinesib 2004 Completed initial public offering 2004 Completed mezzanine (Series E) financing 2003 Selected cardiac muscle activator for development 2003 Initiated Phase 1 clinical trial of ispinesib 2002 Selected KSP inhibitor for development 2001 Series C financing 2000 Series B financing 1999 Series A financing 1998 Company operations begin 1998 Cytokinetics is founded 1998
Our Vision

The vision behind our mission

Cytokinetics was founded in 1997 by four pioneers in the field of muscle biology: James Sabry, M.D., Ph.D.; James Spudich, Ph.D.; Ronald Vale, Ph.D.; and Lawrence S.B. Goldstein, Ph.D. Operations began in 1998 in South San Francisco, California. Their academic research and discoveries relating to the cytoskeleton, cell mechanics and molecular motor proteins formed the scientific platform for the company. Upon its founding, Cytokinetics pursued multiple therapeutic programs in cancer, cardiovascular disease, and inflammatory and infectious diseases, but in 2008 the company discontinued research activities in oncology and realigned with a focus to muscle biology. Since then, the company has built a robust pipeline of sarcomere-directed therapies with promise for people living with diseases characterized by muscle weakness, loss and dysfunction.

Today, we are a team of innovators, creators, solution-seekers and dreamers working collaboratively for the benefit of the patients we serve. With three late-stage potential medicines in development and more on the horizon, we are pursuing our vision to be the leading muscle biology biopharmaceutical company that meaningfully improves the lives of patients with diseases of impaired muscle function through access to novel medicines arising from its research.